Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer

22Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Introductions: Phospho-PRAS40Thr246 (phosphorylated proline-rich Akt substrate of 40 kilodaltons at Thr246) is a biomarker for phosphatidylinositol 3-kinase (PI3K) pathway activation and AKT inhibitors sensitivity. Material and methods: In this study, we immunohistochemically investigated the expression of phospho-PRAS40Thr246 in 141 gastric cancer tumors, and evaluated its clinicopathological and prognostic significance. Results: Sixty-four cases (45.4%) were defined as phospho-PRAS40Thr246 positive. Phospho-PRAS40Thr246 correlated positively with lymph node metastasis, lymphatic infiltration, vascular infiltration and shorter survival. Furthermore, phospho-PRAS40Thr246 is an independent prognostic factor for gastric cancer. Conclusions: Our data suggest that phospho-PRAS40Thr246 was frequently expressed in gastric cancers, and correlated with malignant progression and poor prognosis of patients. PI3K pathway-targeted therapies should be considered in the future treatment of gastric cancers.

Cite

CITATION STYLE

APA

Lu, Y. Z., Deng, A. M., Li, L. H., Liu, G. Y., & Wu, G. Y. (2014). Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer. Archives of Medical Science, 10(1), 149–153. https://doi.org/10.5114/aoms.2013.36927

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free